|| List of recent Peritoneal-related patents
| Methods and compositions for treating mammalian nerve tissue injuries|
To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury.
| Patient simulation system for medical services or diagnostic machines|
A system, method, and apparatus for a patient simulator that interacts with a diagnostic or therapeutic medical device. The system includes a computing device coupled to a patient module.
| Method and apparatus for monitoring a treatment of a patient, preferably for monitoring hemodialysis, hemodiafiltration, and/or peritoneal dialysis|
The present invention pertains to a method for monitoring a treatment of a patient, preferably for monitoring hemodialysis, hemodiafiltration and/or peritoneal dialysis, the method comprising the steps of irradiating a sample of a dialysis liquid used in the treatment with irradiation light of at least a first irradiation wavelength, detecting light emitted by the irradiated sample in at least a first detection wavelength, the detection wavelength being different from the first irradiation wavelength, and determining the presence and/or concentration of at least one analyte in the sample on the basis of the detected light.. .
|Automated peritoneal dialysis cycler and methods of use|
Automated peritoneal dialysis (apd) cycler systems and methods are disclosed. The apd cycler can include a heater tray with load cells configured to measure the weight of fluid contained within a heater bag and/or a drain bag.
|Method of performing peritoneal dialysis using pneumatic valves|
A method of performing peritoneal dialysis includes: (i) locating a supply of fresh dialysis fluid above a patient's peritoneal cavity; (ii) locating a drain or a drain container below the patient's peritoneal cavity; (iii) connecting a supply line to the supply of fresh dialysis fluid and the patient's peritoneal cavity; (iv) connecting a drain line to the patient's peritoneal cavity and the drain or drain container; (v) pneumatically opening a supply line valve during a fill cycle; (vi) gravity filling the patient's peritoneal cavity with the supply line valve open during the fill cycle; (vii) pneumatically opening a drain line valve during a drain cycle; and (viii) draining the patient's peritoneal cavity with the drain line valve open during the drain cycle.. .
|Block copolymer for intraperitoneal administration containing anti-cancer agent, micelle preparation thereof, and cancer therapeutic agent comprising the micelle preparation as active ingredient|
A therapeutic agent as a micelle preparation, comprising a copolymer having a hydrophilic polymeric moiety and a polycarboxylic acid derivative moiety; and an anti-cancer agent bonding to or encapsulated in the copolymer, wherein the micelle preparation may exhibit sustained drug release capability, and enables an extension of a retention time period of the anti-cancer agent in an abdominal cavity, is provided. A superior life-prolonging effect was found in an intraperitoneal administration mouse model compared with a case in which only an encapsulated drug is administered, and thus the present invention was completed accordingly..
|Systems and methods for treating chronic liver failure based on peritoneal dialysis|
An artificial liver system for treating liver failure includes a reservoir to provide albumin-containing dialysis fluid to the patient's peritoneum, an implantable device including a pump to pump the fluid from the peritoneum to the bladder via respective catheters, control circuitry, battery and transceiver; a charging and communication system configured to periodically charge the battery and communicate with the implantable device to retrieve data reflective of the patient's health; and monitoring and control software, suitable for use with conventional personal computers, for configuring and controlling operation of the implantable device and charging and communication system. The monitoring and control software allows a treating physician to remotely adjust the volume, time, and frequency with which fluid is pumped from the peritoneal cavity to the bladder based on the data reflective of the patient's health..
|High flux basket catheter for efficient, continuous flow peritoneal dialysis|
A catheter for use in continuous flow peritoneal dialysis comprising an inflow tube and outflow tube, both connected on one end to a dialysis machine. The inflow tube is divided into a plurality of inflow auxiliary tubes, and the outflow tube is divided into a plurality of outflow auxiliary tubes, with all auxiliary tubes encased in a single external tube.
|High flux basket catheter for efficient continuous flow peritoneal dialysis|
A catheter for use in continuous flow peritoneal dialysis comprising an inflow tube and an outflow tube, wherein both are connected on one end to a dialysis machine. The inflow tube is divided into a plurality of smaller inflow auxiliary tubes, and the outflow tube is divided into a plurality of smaller outflow auxiliary tubes.
|Surgical access system and related methods|
A surgical access system including a tissue distraction assembly and a tissue retraction assembly, both of which may be equipped with one or more electrodes for use in detecting the existence of (and optionally the distance and/or direction to) neural structures before, during, and after the establishment of an operative corridor to a surgical target site. Some embodiments of the surgical access system may be particularly suited for establishing an operative corridor to a surgical target site in the spine.
|Citrullinated histone h3 (cit h3) in septic shock|
Methods of diagnosing sepsis, severe sepsis, or septic shock and predicting prognosis in subjects with septic shock, based on levels of citrullinated histone h3 (cit h3) in the subject, e.g., in a sample comprising serum (e.g., whole blood, serum, or plasma), cerebrospinal fluid, urine, saliva, or peritoneal fluid from the subject.. .
|Mesothelin vaccines and model systems|
Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic t cell response.
|Composite absorbable/biodegradable rings for controlled drug delivery|
A fiber-reinforced composite ring for the controlled release of at least one bioactive agent includes a biocompatible matrix reinforced with absorbable/biodegradable fibers capable of providing the mechanical properties needed for inserting and maintaining the ring in a body cavity for a desired period of time. Such ring system as can be used for the intravaginal, intraperitoneal, and subcutaneous delivery of at least one bioactive agent, including those used as contraceptives, antimicrobial agents, and/or antiviral agents, as well as those for the treatment of cancer..
|Method and apparatus for inducing therapeutic hypothermia|
Methods and apparatus for delivering therapeutic hypothermia to a patient are provided which may include any number of features. One feature is a hypothermia system comprising a fluid source, a heat exchanger assembly, a catheter in fluid communication with the fluid source, and a pump system configured to infuse hypothermic fluid into a patient cavity and extract hypothermic fluid from the patient cavity.
|Peritoneal dialysis systems, devices, and methods|
An automated peritoneal dialysis system provides various features including prescription-driven dialysis fluid preparation, an integrated disposable fluid circuit, and sensor capabilities that allow accurate filing and draining control with high safety margins. Features include a peritoneal fluid circuit with a pressure sensor at either end and methods and devices for using the pressure signals.
|Access systems and methods of intra-abdominal surgery|
An access system includes a proximal handle, an overtube coupled to the handle, and an endoscope port extending through handle and overtube sized for receiving an endoscope therethrough. The overtube includes anatomic wall securing system that secures a distal portion of the overtube within a hole in the anatomic wall.
|Methods and compositions for treating recurrent cancer|
The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as nab-paclitaxel or abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.. .
|Method of mending a groinal defect|
A method of mending a groinal defect such as an indirect inguinal hernia, a direct inguinal hernia, and/or a femoral hernia. A space between the external oblique aponeurosis and the internal oblique aponeurosis is dissected superiorly and laterally to create a site for receiving a lateral portion of a prosthetic repair patch.
|Peritoneal drain and infusion|
A method to remove ascites from a mammalian body including: draining ascites from the peritoneal cavity to the bladder of the mammalian body, and evacuating the drained ascites out of the bladder. The method may be practiced with a valved fistula implanted into the bladder to form a passage between the peritoneal cavity and the bladder..
|Substituted aromatic sulfur compounds and methods of their use|
Wherein d, n, ra, rb, and rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula ii for treating or reducing the risk of peritoneal carcinomatosis in a patient.. .
A pharmaceutical composition for intraperitoneal delivery of an anti-neoplastic agent is provided for treating cancers associated with aberrant mucin expression, preferably ovarian cancer and pancreatic, prostate, metastatic breast, bladder and lung cancers. The composition comprises nanomicelles loaded with the anti-neoplastic agent, and antibodies such as anti-muc16, anti-muc1 or anti-muc4 are conjugated to these nanomicelles.
|Hybrid blood and peritoneal dialysis treatment systems and methods|
A method for a hybrid blood and peritoneal dialysis (“pd”) machine comprising: (i) determining whether a previous treatment left a last fill of dialysate in a patient's peritoneum; (ii) if a next treatment is a pd treatment, and if the previous treatment did not leave the last fill of dialysate, causing a pd treatment in which a first cycle is a fill cycle to be initiated; (iii) if the next treatment is a pd treatment, and if the previous treatment did leave the last fill of dialysate, causing a pd treatment in which a first cycle is a last fill drain cycle to be initiated; and (iv) if the next treatment is a blood treatment and if the previous treatment did leave the last fill of dialysate, causing a blood treatment including a last fill drain cycle to be initiated.. .
|Targeted oncolytic adenovirus for treatment of human tumors, constrcution method and application thereof|
An oncolytic adenovirus vector and its potential application in cancer treatment and vaccination. The inventive vector (named ad-td-hil12) is derived from the human adenovirus group c type 5, more particularly including deletion of three adenovirus genes e1a-cr2, e1b19k and e3gp-19k, and a fused cdna sequence of p35 and p40 subunit of human il12 placed under the control of the e3gp-19k promoter.
|Oral medicinal composition for patients undergoing peritoneal dialysis and method for using same|
The present invention provides an oral medicinal composition for peritoneal dialysis patients to suppress an increase of carbonyl compounds and/or advanced glycation/lipoxidation end products (ages) in the peritoneal cavity and peritoneal tissue after intraperitoneal administration of a glucose-containing peritoneal dialysis fluid, the oral medicinal composition comprising a pharmaceutically acceptable salt of pyridoxamine as an active ingredient.. .
|Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions|
Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions are provided. A novel cause of aseptic peritonitis is provided—aseptic peritonitis associated with gram positive microbial contamination of a dialysis solution.
|Peritoneal dialysis systems and methods having graphical user interface|
A peritoneal dialysis machine including a membrane pump and a touch screen display that includes a mode-indicating portion and an operation-descriptive portion, the mode-indicating portion having a plurality of touch sensitive indicia each indicating one of a plurality of modes in which the machine can operate, the display being used to keep a patient continually informed of which one mode of at least three operating modes the machine is operating in, as the operation-descriptive portion changes to display details of a specific operation being carried out within the one mode, the indicia for each of the three operating modes always being visible to the patient while the machine is operating, the operating mode being selected by the patient touching one of the indicia on the screen.. .
|Stepper motor driven peritoneal dialysis machine|
A peritoneal dialysis system includes: an enclosure including an actuation surface and a door; a stepper motor housed by the enclosure; a pump head and a solid pump piston structurally linking the pump head to the stepper motor; and a disposable unit accepted by the enclosure, the disposable unit including a flexible membrane attached to a rigid piece, the actuation surface of the enclosure and the disposable unit so configured and arranged that when the stepper motor turns and consequently translates the solid pump piston and the pump head towards the door, the pump head physically contacts and stretches the membrane from a relaxed position to a stretched position, and when the stepper motor turns and consequently translates the solid pump piston and the pump head away from the door, the membrane follows the pump head and transitions from the stretched position to the relaxed position.. .
|Simulation of patient drain phase in peritoneal dialysis|
A method of modeling a patient's peritoneal dialysis drain phase includes (a) modeling a first segment of a drain phase curve as having a constant flowrate, (b) modeling a second segment of the drain phase curve as having a decaying exponential flowrate, and (c) ensuring that a drain flowrate does not fall below a certain level during therapy by incorporating a switching component so that (i) at a first time the first segment is active while the second segment is inactive and (ii) at a second time the first segment is inactive while the second segment is active.. .
|Universal connector for drainage of bodily fluids|
The present disclosure describes an adapter for use with two connectors in, for example, a pleural, peritoneal or other bodily fluid drainage system. The adapter allows the use of the disposal bag from one manufacturer to be used with the catheter of another.
|System and method for selection of stored dialysis therapy prescriptions|
In an embodiment, an automated peritoneal dialysis (“apd”) machine includes at least one pump, a logic implementer storing a plurality of therapy prescriptions by which to operate the at least one pump, each therapy prescription pre-approved for a particular patient, and an input device operating with the logic implementer to allow the patient to select one of the therapy prescriptions for a particular therapy. In another embodiment, the input device operating with the logic implementer allows a doctor/clinician to select or approve one of the therapy prescriptions to be run on the apd machine.
|Treatment of peritoneal injury using jak inhibitors|
The invention provides, in certain embodiments, a method of preventing and/or treating peritoneal injury and/or diminished function by administering an effective amount of one or more inhibitors of jak. The invention also provides a pharmaceutical composition including a jak inhibitor for the treatment of peritoneal injury and/or diminished function.
|Sensing of gaseous leakage into body for early detection of colorectal anastomotic leakage|
Technologies are generally described for a system for detecting the presence of gas in the intraperitoneal space of the abdominal cavity and indicating anastomotic leakage. A sensing device may be implanted inside the abdominal cavity of a body near the location of an anastomosis.
|Peritoneal dialysis connection system and method for using ultraviolet light emitting diodes|
Peritoneal dialysis systems and methods are provided by the present disclosure. In a general embodiment, a peritoneal dialysis system includes a peritoneal dialysis fluid supply, a supply line in fluid communication with the peritoneal dialysis fluid supply and terminating at a supply connector, a patient connector in fluid communication with a patient's indwelling catheter, a device configured to connect the supply connector to the patient connector without a user having to physically contact the supply connector or the patient connector, and a housing placeable around the connecting device and including a plurality of ultraviolet (“uv”) light-emitting diodes (“led's”) positioned to direct energy towards at least one of the supply connector and the patient connector..
|Multimodal dialysis system|
A dialysis device for operation in multiple modes and for maintaining a known gradient of potassium ion or other electrolyte between the blood of a patient and a dialysate fluid is described. The dialysis device is capable of being used for hemodialysis or peritoneal dialysis, and the dialysis device is capable of operation with a dialysate purification unit outside of a clinical setting or with a supply of water that can be supplied in a clinical setting.
|Blood glucose control system|
Techniques are used for adaptation of drug-administration parameters that control insulin delivery in a blood glucose control system. One technique provides long-term adaptation of a nominal basal infusion rate, adapting to longer-term changes in a patient's needs due to growth, illness, hormonal fluctuations, physical activity, aging, etc.
|Medical apparatus with a socket unit for the connection of a device for supplying medical fluids|
A medical apparatus includes a socket unit for connecting a plug unit of a device for supplying medical fluids, in which the medical apparatus is in particular an extracorporeal blood treatment apparatus, for example an extracorporeal dialysis apparatus or an apparatus for peritoneal dialysis, or an apparatus for filling the device for supplying medical fluids. The socket unit comprises connection pieces for the connection of connectors of a plug unit, so that a flow connection can be produced for supplying or discharging a fluid.
|Medical apparatus having a socket unit for connection of a device for supplying medical fluids, and device for supplying medical fluids having a plug unit for connection to a medical apparatus|
A medical apparatus includes a socket unit for connection to a plug unit belonging to a device for supplying medical fluids for a blood treatment apparatus, the medical apparatus being in particular an extra-corporeal blood treatment apparatus such for example as an extra-corporeal dialysis apparatus or an apparatus for peritoneal dialysis, or an apparatus for filling the device for supplying medical fluids. A device for supplying medical fluids for a blood treatment apparatus, which has a plug unit for connection to a socket unit of a medical apparatus, is also described.